enuresis/arginine

A response to desmopressin spray is only seen in a proportion of children with enuresis. To investigate whether response is related to nocturnal levels of arginine vasopressin (AVP) 35 children with enuresis, aged 8 to 14 years, had plasma AVP measurements overnight before entering a double blind

Intranasal administration of 1-deamino 8-D-arginine vasopressin (DDVAP) used for treatment of nocturnal enuresis (NE), might be expected to have various effects on the nasal mucosa, e.g. altering the clearance by the mucociliary apparatus. We evaluated two samples (brushes) of epithelial surface

OBJECTIVE To test the hypothesis that 1-desamino-8-D-arginine vasopressin (dDAVP) has an effect on prepulse inhibition (PPI) of startle in patients with primary monosymptomatic enuresis (PME), thus indicating a central effect. METHODS Patients with PME (n = 21, age 6 to 12 years) were enrolled in a

The objective of these studies was to determine a relationship between primary nocturnal enuresis and arginine vasopressin (AVP) secretion. The first study compared 24-h AVP secretion profiles of enuretic (n = 9) and non-enuretic children (n = 8). Blood samples were collected at 1-h intervals for 24

The effect of desamino-D-arginine vasopressin was investigated in a double-blind study of 37 children more than 9 years old with nocturnal enuresis resistant to conventional therapy. A significant reduction of wet nights was observed but as soon as the medication was stopped the children reverted to

OBJECTIVE To determine any possible adverse effect of 1-deamino 8-D-arginine vasopressin (DDAVP) spray on nasal cytology and mucociliary clearance in patients with nocturnal enuresis. METHODS Twenty-two children aged 6-16 enrolled in the study. Epithelial surface cells samples were taken from the

OBJECTIVE The aim of this group of studies was to determine the relationship between primary nocturnal enuresis and arginine-vasopressin (AVP) secretion. METHODS The first study compared the 24-hour AVP secretion profiles of an enuretic group and a control group. Blood samples were collected every

OBJECTIVE To identify the relationship between nocturnal AVP deficiency, nocturnal polyuria (NP), and low urinary osmolality in children suffering of primary monosymptomatic nocturnal enuresis (NE). METHODS The study included 50 children (28 males and 22 females) with primary monosymptomatic NE and

Desmopressin responders tend to have a large volume of urine production at night, in contrast to desmopressin refractory patients who often produce normal volumes of urine. Controls and adolescent/adult primary monosymptomatic nocturnal enuretics were included in a study measuring urine volume and

BACKGROUND Treatment of primary nocturnal enuresis using 1-deamino-8-D-arginine-vasopressin is based on the hypothesis that antidiuretic hormone (arginine vasopressin [AVP]) secretion is insufficient during the night. Persisting doubts about the theoretical background of this treatment and first

Arginine vasopressin preparations have been used in the treatment of diabetes insipidus for many years. Compared with older antidiuretic agents, the synthetic analog desmopressin is more potent, longer acting and easier to use. It is available for intravenous, subcutaneous and intranasal

Desmopressin is a potent antidiuretic for nocturnal enuresis with few and mostly insignificant adverse reactions. Almost 80 years ago, the antidiuretic effects of extracts of the posterior pituitary were first reported. The molecular structure of the peptide vasopressin arginine vasopressin (AVP)

Treatment of primary nocturnal enuresis (PNE) using desmopressin (dDAVP) is based upon the hypothesis that antidiuretic hormone (arginine vasopressin (AVP) secretion is insufficient during the night. Persisting doubts about the theoretical background of this treatment gave reason to different

Monosymptomatic nocturnal enuresis, a heterogeneous condition, is frequently treated in children aged >5 years. Of the various treatment options, enuresis alarm has been widely advocated as being effective for treating nocturnal enuresis, while extracorporeal pelvic floor magnetic stimulation for